Obesity as a Risk Factor for Coronary Events in Japanese Patients with Hypercholesterolemia on Low-Dose Simvastatin Therapy

Yasushi Saito¹, Toru Kita², Hiroshi Mabuchi³, Masunori Matsuzaki⁴, Yuji Matsuzawa⁵, Noriaki Nakaya⁶, Shinichi Oikawa⁷, Jun Sasaki⁸, Kazuaki Shimamoto⁹, and Hiroshige Itakura¹⁰

¹Chiba University Graduate School of Medicine, Chiba, Japan
²Kobe City Medical Center General Hospital, Kobe, Japan
³Kanazawa University Graduate School of Medicine, Kanazawa, Japan
⁴Yamaguchi University Graduate School of Medicine, Ube, Japan
⁵Sumitomo Hospital, Osaka, Japan
⁶Nakaya Clinic, Tokyo, Japan
⁷Nippon Medical School, Tokyo, Japan
⁸International University of Health and Welfare Graduate School of Clinical Trial Management, Fukuoka, Japan
⁹Sapporo Medical University School of Medicine, Sapporo, Japan
¹⁰Ibaraki Christian University, Hitachi, Japan

Aim: We previously reported that obesity (defined as a body mass index (BMI) ≥25 kg/m²) was not an independent risk factor for coronary heart disease (CHD) in hypercholesterolemic patients without a history of CHD from the Japan Lipid Intervention Trial (J-LIT). In this study, the obese J-LIT subgroup was further analyzed to assess CHD risk.

Methods: In the J-LIT study, patients received simvastatin treatment (usually at 5 mg/day) for 6 years. A total of 38,385 patients (mean age: 57.7 ± 7.9, 12,111 men) without prior CHD and/or stroke were analyzed.

Results: In this cohort, 181 CHD (acute myocardial infarction or sudden cardiac death) were observed. Obesity (n = 12,929) was not an independent risk factor for CHD (relative risk: 1.18, 95% confidence interval: 0.87–1.59) after adjustment for the major risk known factors, such as age, sex, hypertension, diabetes mellitus (DM), and smoking. However, blood pressure, triglycerides, and fasting plasma glucose all increased, while high-density lipoprotein-cholesterol decreased, with increased BMI. The percentage of patients having two or three risk factors (such as dyslipidemia, hypertension, and DM) also increased with increased BMI.

Conclusions: Obesity was not an independent risk factor for CHD in hypercholesterolemic patients on statin therapy; however, it is important to control obesity, a condition in which CHD risks accumulate, in order to improve associated risk factors along with the treatment of each risk factor, thus further reducing the risk of CHD.


Key words: Obesity, Body mass index, Risk factors for coronary events, Simvastatin

Introduction

According to the World Health Organization (WHO)¹, the prevalence of both overweight (body mass index (BMI) ≥25 kg/m²) and obesity (BMI ≥30 kg/m²) is increasing worldwide at an alarming rate in both developing and developed countries. The United States national survey showed that adults who were overweight or obese increased from 56% to 66% between 1988–94 and 2003–4².³. Almost 108 million adults in the USA are either overweight or obese and their weight increases the risk of various major
diseases, including hypertension\(^4\), dyslipidemia\(^5\), diabetes mellitus (DM)\(^6, 7\), coronary heart disease (CHD)\(^8\), stroke\(^9\), and cancer\(^10\). It is now generally accepted that obesity should not be classified as a 'disease', but rather as a 'risk factor' in the cluster of factors for atherosclerotic disease\(^8, 11, 12\). Thus, obesity is often associated with a combination of cardiovascular and metabolic risk factors known as metabolic syndrome. This syndrome is typically characterized by abdominal obesity, dyslipidemia, hypertension, and a raised fasting plasma glucose (FPG) level\(^13\). In 2005, metabolic syndrome and its diagnostic criteria were also defined in Japan\(^14\).

The prevalence of obesity in Japan is still relatively low compared with in Western countries, but eating a Westernized high-fat, high-energy diet and living a sedentary lifestyle have increased the number of obese people\(^1\). According to the 2004 National Health and Nutrition Survey, 30.9% of Japanese men and 22.7% of women were obese (≥25 kg/m\(^2\)). As observed in Western countries, obesity and its associated diseases have increased, and consequently national healthcare costs have also increased. Recently, the Japanese Health, Labour and Welfare Ministry emphasized the importance of preventing obesity and its associated diseases (or lifestyle-related diseases), especially metabolic syndrome.

The Japan Lipid Intervention Trial (J-LIT) was a prospective nationwide cohort study of a large number of patients with hypercholesterolemia who received open-label treatment with simvastatin (5 to 10 mg/day). The study was carried out for 6 years by physicians managing their patients in daily practice to evaluate the relationship between cardiovascular disease and serum lipid levels\(^15, 16\). Analysis of the data in this study has already shown that dyslipidemia, DM, and hypertension are significant risk factors for CHD, but has failed to demonstrate that obesity is an independent risk factor for Japanese patients who have hypercholesterolemia with or without a history of CHD. Thus, the risk related to obesity may disappear after adjusting for confounding factors, such as DM and hypertension.

In the present sub-analysis of the J-LIT study population, we examined the CHD risk of obesity in a different subgroup from that previously analyzed, after excluding all high risk patients with a history of CHD or stroke.

**Methods**

**Study Design**

The design of J-LIT has been described in detail elsewhere\(^17, 18\). Patients were generally treated with 5 mg/day simvastatin in an open-label trial. All patients, including those who discontinued simvastatin for any reason, were monitored for 6 years. Serum lipid levels were determined in the laboratories of the participating institutions. Dietary and exercise therapy for dyslipidemia were selected by the investigators and there were no restrictions on medical treatment for complications. The serum low-density lipoprotein cholesterol (LDL-C) level was calculated by Friedewald's formula.

Body weight, blood pressure (BP), FPG, and serum lipids were measured every 6 months after enrollment, and patients were asked about compliance with treatment, cigarette smoking, alcohol consumption, and exercise. Each patient was informed of the purpose of the study, the effects of simvastatin, and the need for long-term treatment. Only verbal informed consent was obtained from the patients, because a commercially available drug preparation was used in the study.

**Subjects**

The J-LIT study enrolled 52,421 patients, including men aged 35–70 years and post-menopausal women aged ≤70 years, with a serum total cholesterol (TC) level ≥220 mg/dL. Exclusion criteria were uncontrolled DM, serious concomitant hepatic or renal disease, secondary hypercholesterolemia, and malignancy or any other illness with a poor prognosis. Patients with a history of CHD/stroke were excluded from this sub-analysis to simplify the assessment of the risk of obesity itself. A total of 38,385 patients who had hypercholesterolemia and no prior CHD/stroke were analyzed. The follow-up period was 6 years.

**Endpoint and Definitions of Major Risk Factors**

The primary endpoint was coronary events (acute myocardial infarction or sudden cardiac death). The first event that occurred during the study period was counted once in each patient. All coronary events were reviewed and determined by the Endpoint Classification Committee.

Hypertension was defined as present if diagnosed by the investigators or if the patient was on antihypertensive therapy or had a systolic BP/diastolic BP ≥140/90 mmHg. High BP was defined as a diagnosis of hypertension or a systolic/diastolic BP ≥130/85 mmHg according to the diagnostic criteria of metabolic syndrome in Japan\(^14\). DM was defined as present if diagnosed by an investigator or if the patient was on drug treatment for DM or had an FPG ≥126 mg/dL. High FPG was defined as DM or an FPG
FPG ≥110 mg/dL. Dyslipidemia was defined as a triglyceride (TG) level ≥150 mg/dL and/or high-density lipoprotein-cholesterol (HDL-C) level <40 mg/dL. Obesity was defined as BMI ≥25 kg/m² at baseline, which is the usual criterion for Japanese subjects.\(^1\)

### Statistical Analysis

All data, including the findings obtained after the termination of simvastatin therapy, were assessed by survival analysis. We calculated the relative risk and 95% confidence interval for the endpoint in each subgroup relative to the reference category by using the Cox proportional-hazards model with adjustment for gender, age at baseline (as a continuous variable), BMI, increased FPG, hypertension, cigarette smoking, alcohol consumption, and physical activity. The mean lipid levels were calculated from the data obtained throughout the treatment period. Mean values for serum lipid levels and age were tested with unpaired t test, and the prevalence of baseline characteristics were tested with the chi-square test to compare obesity (+) and obesity (−) groups. For analysis of continuous variables, groups divided by BMI were assessed using analysis of covariance (ANCOVA) with adjustment for gender and age. Results are expressed as the mean ± SD or median (interquartile range). For all statistical analyses, \(p < 0.05\) was considered significant. All calculations were performed using SAS software (version 8.02; SAS Institute, Inc., Cary, NC, USA).

### Results

#### Follow-Up and Treatment

The mean follow-up period was 5.4 years. Most patients were treated with 5 mg/day simvastatin throughout the study period.

#### Patient Profile

The baseline characteristics of the patients are shown in Table 1. Men accounted for 31.6% and the mean age was 57.7 ± 7.9 years. Almost half of the patients had hypertension and 15.8% had DM. According to the above-mentioned definition of obesity, 12,929 patients were obese and the other 25,456

| Table 1. Patient Characteristics and Lipid Profile at Baseline |
|---------------------------------|-----------------|-----------------|-----------------|-----------------|
|                                | Total           | Obesity (+)     | Obesity (−)     | \(p\)-value     |
| Number of patients             | 38,385          | 12,929          | 25,456          | <0.001          |
| Male (%)                       | 31.6            | 34.6            | 30.0            | <0.001          |
| Age (years)                    | 57.7 ± 7.9      | 56.9 ± 8.2      | 58.1 ± 7.7      | <0.001          |
| Hypertension (%)               | 45.8            | 55.6            | 40.8            | <0.001          |
| High Blood Pressure (%)        | 78.5            | 85.7            | 74.8            | <0.001          |
| Diabetes mellitus (%)          | 15.8            | 18.6            | 14.3            | <0.001          |
| FPG ≥110 mg/dL (%)             | 2.7             | 3.3             | 2.4             | <0.001          |
| ECG abnormality (%)            | 12.8            | 14.3            | 12.1            | <0.001          |
| Family history of CHD (%)      | 4.9             | 5.0             | 4.8             | 0.355           |
| Smoking habit (%)              | 16.7            | 19.2            | 15.5            | <0.001          |
| Alcohol consumption (%)        | 29.2            | 32.8            | 27.4            | <0.001          |

Serum lipid levels at baseline

<table>
<thead>
<tr>
<th>Lipid</th>
<th>Total (mg/dL)</th>
<th>Obesity (+) (mg/dL)</th>
<th>Obesity (−) (mg/dL)</th>
<th>(p)-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>TC</td>
<td>269.9 ± 34.6</td>
<td>269.3 ± 38.0</td>
<td>270.3 ± 32.7</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>LDL-C</td>
<td>182.5 ± 33.5</td>
<td>181.1 ± 32.7</td>
<td>183.2 ± 33.8</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>TG</td>
<td>156 (109–228)</td>
<td>180 (126–259)</td>
<td>145 (102–211)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>HDL-C</td>
<td>53.0 ± 15.1</td>
<td>49.8 ± 13.5</td>
<td>54.6 ± 15.6</td>
<td>&lt;0.001</td>
</tr>
</tbody>
</table>

Serum lipid levels during treatment

<table>
<thead>
<tr>
<th>Lipid</th>
<th>Total (mg/dL)</th>
<th>Obesity (+) (mg/dL)</th>
<th>Obesity (−) (mg/dL)</th>
<th>(p)-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>TC</td>
<td>220.4 ± 29.5</td>
<td>220.5 ± 30.1</td>
<td>220.3 ± 29.1</td>
<td>0.491</td>
</tr>
<tr>
<td>LDL-C</td>
<td>133.7 ± 29.0</td>
<td>133.5 ± 29.2</td>
<td>133.8 ± 28.9</td>
<td>0.394</td>
</tr>
<tr>
<td>TG</td>
<td>142 (107–191)</td>
<td>158 (121–211)</td>
<td>134 (102–179)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>HDL-C</td>
<td>55.3 ± 13.7</td>
<td>52.3 ± 12.1</td>
<td>56.9 ± 14.2</td>
<td>&lt;0.001</td>
</tr>
</tbody>
</table>

Obesity, body mass index ≥25 kg/m².
FPG, fasting plasma glucose; ECG, electrocardiogram; CHD, coronary heart disease; TC, total cholesterol; LDL-C, low-density lipoprotein cholesterol; TG, triglycerides; HDL-C, high-density lipoprotein cholesterol.

TC, LDL-C and HDL-C were expressed as mean ± standard deviation, TG is presented as median (interquartile range).

\(p\)-value, obesity (+) vs. obesity (−)
were not. The rates of hypertension (55.6%) and DM (18.6%) in the obese group were higher than in the non-obese group (40.8 and 14.3%, respectively). The median TG level of the obese group (180 mg/dL at baseline and 158 mg/dL during treatment) was higher than that of the non-obese group (145 mg/dL and 134 mg/dL, respectively), while the HDL-C level of the obese group at baseline and during treatment (49.8 mg/dL and 52.3 mg/dL, respectively) was lower than that of the non-obese group (54.6 mg/dL and 56.9 mg/dL, respectively). The mean serum TC and LDL-C levels were similar in obese and non-obese groups.

Risk Factors for Coronary Events

During the treatment period, coronary events occurred in 181 (113 in non-obese patients and 68 in obese patients) of the 38,385 patients analyzed (Table 2). Obesity (defined as BMI $\geq 25$ kg/m$^2$) was not an independent risk factor for coronary events in this cohort after adjustment for other risk factors, as reported previously$^{15}$. A high TG level ($\geq 150$ mg/dL) was also not a risk factor for coronary events, but a low HDL-C level ($< 40$ mg/dL) was a risk factor. High BP ($\geq 130$ mmHg systolic and/or $\geq 85$ mmHg diastolic, or diagnosed hypertension) and increased FPG ($\geq 110$ mg/dL or diagnosed DM) were also significant risk factors for coronary events.

Influence of Obesity on Blood Pressure, Serum Lipids, and Fasting Plasma Glucose

Patients were stratified into 5 groups according to their BMI values, and the effect of an increase in BMI on the systolic BP, diastolic BP, serum lipids, and FPG was assessed (Table 3). The systolic BP, diastolic BP, TG, and FPG all gradually increased, while HDL-C decreased, with an increment of BMI. The mean systolic/diastolic BP was 133.2/77.6 mmHg, median TG was 119 mg/dL, and mean FPG was 107.0 mg/dL in patients with a BMI $\leq 20.0$ kg/m$^2$, while these values respectively increased to 145.1/86.1 mmHg, 185 mg/dL, and 116.0 mg/dL in patients with BMI $\geq 27.5$ kg/m$^2$. Serum HDL-C decreased from 60.4 at BMI $\leq 20.0$ kg/m$^2$ to 49.0 mg/dL at BMI $\geq 27.5$ kg/m$^2$; however, a small correlation between serum TC or LDL-C levels and the BMI was observed. The influence was similar in men and women (Table 4).

Increased Risk of Coronary Events with Clustering of Risk Factors

The risk of coronary events adjusted for age, sex, and cigarette smoking increased significantly along with the increased number of risk factors, such as dyslipidemia (TG $\geq 150$ mg/dL and/or HDL-C $< 40$ mg/dL), hypertension, DM, and obesity (BMI $\geq 25$ kg/m$^2$). In patients with all four risk factors, the risk of coronary events was 3.3-fold higher than in patients with no or one risk factor (Fig. 1).

Discussion

Overweight and obesity are of particular concern for several reasons. Both conditions substantially increase the risk of morbidity and mortality due to hypertension, dyslipidemia, diabetes, CHD, and
stroke, as well as being related to sleep apnea and respiratory problems, gallbladder disease, and several cancers, as has been mainly reported in Western countries. In particular, abdominal obesity is associated with the cluster of cardiovascular and metabolic risk factors known as metabolic syndrome.

NHANES III showed that morbidity due to hypertension and dyslipidemia increased as the BMI increased in both men and women, and morbidity from hypertension was 2-fold higher in patients with BMI ≥30 kg/m² than in those with BMI <25 kg/m². In addition, the prevalence of a high serum TC and LDL-C, low-density lipoprotein cholesterol; TG, triglycerides; HDL-C, high-density lipoprotein cholesterol; FPG, fasting plasma glucose.

Mean ± standard deviation, TG is presented as median (interquartile range). P value for ANCOVA with adjustment for gender and age.
Coronary Events in Obesity

vs. 40.8% in non-obese patients) and DM (18.6 vs. 14.3%). The mean serum TG level was also higher and the mean HDL-C level was lower in the obese group than in the non-obese group at baseline and during treatment. The mean systolic/diastolic BP gradually increased from 133/78 mmHg to 145/86 mmHg along with an increase of the BMI from < 20.0 kg/m² to ≥ 27.5 kg/m². In the same manner, serum TG and FPG increased from 119 mg/dL to 185 mg/dL and from 107 mg/dL to 116 mg/dL, respectively, while serum HDL-C decreased from 60 mg/dL to 49 mg/dL. This association of BMI with BP, FPG, and lipid levels suggests that obesity increases the magnitude of the risk associated with each established risk factor. On the basis of these results, we analyzed the risk of coronary events in patients with BMI ≥ 22.5 kg/m² and compared to those with BMI < 22.5 kg/m²; the risk was slight higher (1.42 \( p = 0.04 \)). The risk of coronary events in patients with BMI > 27.5 kg/m² was not high compared to those with BMI < 27.5 kg/m².

Obesity is also thought to be a potential risk factor for CHD in Japan, but it is still unclear whether it is an independent risk factor. Some Japanese studies have shown that obesity is an independent risk factor for CHD after adjustment for other risk factors, but this was not confirmed by other case-control studies. Shiraishi et al. reported that obesity (BMI ≥ 25 kg/m²) was an independent risk factor for acute myocardial infarction in young and middle-aged men, but not in women, according to the Kyoto Multi-Center Risk Study. In the present analysis and a previous report, however, we did not demonstrate that obesity per se was an independent risk factor for CHD after adjustment for other known risk factors (Table 2).

The reasons for this outcome are not clear. Previous Japanese studies have shown both positive and negative results. Obesity seems to be an independent risk factor for men, but not for women, as mentioned above. The J-LIT subjects included a high percentage of women (68.4%) whose cardiovascular risk was significantly lower than that of men. Because of this high proportion of women in this sub-analysis, obesity might not be an independent risk factor for CHD in men and women. Obesity is closely associated with other strong CHD risk factors, such as hypertension, DM, and dyslipidemia, so these may act as confounding factors for obesity, i.e. the risk related to obesity may decrease after adjustment for these confounding factors. Another possibility is related to the lack of measurement of abdominal obesity or waist circumference in this study. Instead, we used a BMI ≥ 25 kg/m² as the criterion for obesity in Japanese subjects according to the Expert Committee on the Criteria for ‘Obesity’ in Japan, although obesity is defined as BMI ≥ 30 kg/m² and overweight means ≥ 25 kg/m² in Western countries. The difference in the definition of obesity between Japan and Western countries may lead to unexpected results in Japanese subjects.

In this observational cohort study, the risk of coronary events increased significantly with an increase in the number of risk factors, including obesity (BMI ≥ 25 kg/m²), and obesity was one of the potential risk factors in the daily clinical setting, although hypertension, DM, and dyslipidemia acted as confounders (Table 2). In patients having all four of these risk factors, the risk of coronary events was 3.3-fold higher than in patients having no or one risk factor (Fig. 1).

There are some limitations of this study. First, this study is a post-hoc non-randomized, observational subanalysis. Second, we could not investigate the characteristics of metabolic syndrome because waist circumference, which is a criterion for metabolic syndrome, was not examined in the J-LIT study. Further study will therefore be required to characterize metabolic syndrome.

In conclusion, our data clearly demonstrated that obesity enhances the influence of hypertension, DM, and dyslipidemia, and promotes the accumulation of these risk factors in patients, even though obesity was not an independent risk factor for coronary events in Japanese patients with hypercholesterolemia on statin treatment. In addition, the risk of CHD was increased.
in obese patients by comorbidities such as hypercholesterolemia. These results suggest that it is important to manage obesity in order to control associated diseases and modify each risk factor, consequently decreasing the risk of CHD; however, further clinical trials are needed to demonstrate the benefits of weight loss for obese patients.

Notice of Grant Support

This study was partly supported by a grant from Banyu Pharmaceutical Co., Ltd. (Tokyo, Japan). There are no financial conflicts of interest in this study.

References


